Geron Corporation
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes. The company has moved from a development-stage profile into early commercialization, with product sales currently concentrated in the U.S. and a small royalty stream from legacy intellectual property.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCommercial sales of RYTELO, Geron's approved oncology drug for lower-risk MDS.
Small royalty stream tied to sales of products using divested stem cell assets.
Asiakkaat
Geron sells primarily to third-party distributors and specialty pharmacies, which then resell RYTELO to health care providers and patients. The end demand comes from hematologists and oncology practices treating adult patients with lower-risk MDS and transfusion-dependent anemia, with reimbursement and access conditions shaping uptake.
They buy RYTELO for resale and handle prescription intake, distribution, and payment collection.
They prescribe RYTELO to eligible lower-risk MDS patients and drive clinical adoption.
They determine coverage, discounts, and net realized pricing for RYTELO.
They are the ultimate end users of the therapy and the source of treatment demand.
Strategia
Geron's near-term strategy is to scale U.S. commercialization of RYTELO while managing gross-to-net deductions, distribution execution, and reimbursement access. Longer term, the company is trying to expand the drug's reach outside the U.S. and preserve optionality in imetelstat development, while also tightening capital discipline through restructuring and financing flexibility.
Near-term revenue and value creation depend on successful launch execution and physician adoption.
Ex-U.S. markets could extend the product lifecycle and diversify revenue, but require regulatory and reimbursement success.
Commercialization and development remain capital intensive, so the company is reducing overhead and preserving liquidity.
Maantiede
Geron's commercial revenue is currently concentrated in the United States, where RYTELO began shipping in June 2024 and remains the company's only product revenue source. The company also has operating subsidiaries in the United Kingdom and the Netherlands as it prepares for potential international expansion, including the EU, where pricing and reimbursement rules could materially affect commercialization.
Riskit
Geron's business is highly concentrated in RYTELO, so commercial uptake, reimbursement, and distribution execution directly drive the company's prospects. It also faces typical biotech risks around intellectual property, regulatory exclusivity, clinical development, financing needs, and litigation, all of which can materially affect value and liquidity.
- Dependence on RYTELO commercializationVaikutus: KorkeaTodennäköisyys: Korkea
The company says its near-term prospects are wholly dependent on RYTELO, so weak uptake would materially hurt revenue and profitability.
Kohdistuu: Single-product concentration
- Financing and liquidityVaikutus: KorkeaTodennäköisyys: Korkea
Commercialization and development require significant capital, and the company may need additional funding if sales lag or spending rises.
Kohdistuu - Distribution and specialty pharmacy executionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Geron relies on third-party distributors and specialty pharmacies for patient access, data collection, and payment flow.
Kohdistuu: U.S. commercial channel
- Intellectual property and regulatory exclusivityVaikutus: KorkeaTodennäköisyys: Kohtalainen
Loss of protection could allow competitors to develop similar products and weaken RYTELO's commercial position.
Kohdistuu: U.S. and international markets
- Pricing, reimbursement, and gross-to-net pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Chargebacks, rebates, and returns reduce gross sales and can widen if payer mix or access terms worsen.
Kohdistuu: U.S. net product revenue
- Litigation and stock volatilityVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Ongoing securities and derivative lawsuits can create legal costs, management distraction, and share-price volatility.
Kohdistuu: Corporate governance
Kirjanpito
Harkinnanvaraiset erätNet sales depend on estimates for chargebacks, rebates, distributor fees, and returns, which can materially change reported revenue.
Vaikutus: Affects product revenue, receivables, and liabilities
RYTELO is early in launch, so shipment timing and payer mix can create large quarter-to-quarter swings.
Vaikutus: Affects comparability of quarterly revenue and margins
The December 2025 restructuring plan will require severance and related charges as headcount is reduced.
Vaikutus: Affects operating expenses and cash outflows
Borrowings and royalty arrangements can create interest expense, non-cash financing costs, and covenant-related disclosures.
Vaikutus: Affects net loss, leverage, and liquidity presentation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Mereo BioPharma Group plc
MREO · Pharmaceutical Preparations
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing late-stage therapies for rare diseases.
Rigel Pharmaceuticals, Inc
RIGL · Pharmaceutical Preparations
Rigel Pharmaceuticals is a U.S.-based biotechnology company focused on therapies for hematologic disorders and cancer.
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Mesoblast Limited
MESO · Biological Products, (No Diagnostic Substances)
Mesoblast Ltd is a biopharmaceutical company focused on developing and commercializing allogeneic cell therapies based on mesenchymal stromal cells.
Immunome Inc.
IMNM · Pharmaceutical Preparations
Regeneron Pharmaceuticals, Inc
REGN · Pharmaceutical Preparations
Regeneron Pharmaceuticals is a U.S.-based biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases.
Päivitetty: 24.9.2026